How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

HUTCHMED was preparing a New Drug Application (NDA) submission for FRUZAQLA® (fruquintinib), a drug developed for metastatic colorectal cancer.

While the drug had already received approval in China in 2023, the companies were aiming for U.S. market approval. This required extensive clinical pharmacology support, pharmacometrics modeling, and regulatory writing under strict timelines.

This three-year project presented challenges such as variability in data across studies, complexities in exposure-response analysis due to confounding factors, stringent regulatory requirements for QT prolongation assessments, and tight submission deadlines requiring a streamlined and efficient workflow.

• Clinical Pharmacology & Pharmacometrics: Performed gap analysis to inform study design, as well as regulatory and clinical pharmacology strategy ahead of the Phase 3 study; conducted population PK and safety and efficacy exposure-response (ER) modeling for fruquintinib and its major metabolite; and performed concentration-QTc analysis for cardiac safety.
• Regulatory Writing & Submission: Delivered NCA for key studies, provided medical writing for eCTD Module 2.7.2, and expedited delivery by working with the Certara pharmacometrics team as coauthors.
• 项目管理: Effectively coordinated cross-functional teams within Certara to ensure timely delivery in support of the submission under stringent deadlines.

Successful and Timely Submission: Despite data challenges and analytical complexities, Certara’s efficient processes ensured that HutchMed and Takeda met their regulatory filing deadline.

FDA Approval: Fruquintinib received FDA approval in 2023, opening new treatment options for patients with metastatic colorectal cancer.

Streamlined Workflow for Future Submissions: Our parallel report-writing approach set a precedent for accelerating future regulatory submissions, minimizing delays in critical filings.